|
US5770700A
(en)
*
|
1996-01-25 |
1998-06-23 |
Genetics Institute, Inc. |
Liquid factor IX formulations
|
|
US6171586B1
(en)
*
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
|
US6991790B1
(en)
|
1997-06-13 |
2006-01-31 |
Genentech, Inc. |
Antibody formulation
|
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
US20080050367A1
(en)
*
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US7964192B1
(en)
*
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
US6787523B1
(en)
*
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
|
WO2000066155A1
(en)
|
1999-04-30 |
2000-11-09 |
La Jolla Institute For Allergy And Immunology |
Methods for preventing reactivation of latent virus and controlling virus replication
|
|
US7112576B1
(en)
|
1999-12-10 |
2006-09-26 |
Regents Of The University Of Minnesota |
Compositions and methods for cryopreservation of peripheral blood lymphocytes
|
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
WO2002030463A2
(en)
|
2000-10-12 |
2002-04-18 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
WO2002039951A2
(en)
*
|
2000-11-15 |
2002-05-23 |
Globe Immune, Inc. |
Yeast-dentritic cell vaccines and uses thereof
|
|
TWI255272B
(en)
*
|
2000-12-06 |
2006-05-21 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
|
US20020141970A1
(en)
*
|
2001-03-05 |
2002-10-03 |
Pettit Dean K. |
Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
|
|
KR20040065278A
(ko)
*
|
2001-12-21 |
2004-07-21 |
노보 노르디스크 에이/에스 |
변경된 인자 ⅶ 폴리펩티드의 액체 조성물
|
|
PL370656A1
(en)
*
|
2001-12-21 |
2005-05-30 |
Novo Nordisk A/S |
Liquid composition of modified factor vii polypeptides
|
|
CN1607958A
(zh)
|
2001-12-21 |
2005-04-20 |
诺和诺德医疗保健公司 |
因子ⅶ多肽的液体组合物
|
|
DE10204792A1
(de)
*
|
2002-02-06 |
2003-08-14 |
Merck Patent Gmbh |
Lyophilisierte Zubereitung enthaltend Immuncytokine
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
US20040009918A1
(en)
*
|
2002-05-03 |
2004-01-15 |
Hanne Nedergaard |
Stabilised solid compositions of modified factor VII
|
|
EP1517698B2
(en)
|
2002-06-21 |
2017-12-06 |
Novo Nordisk Health Care AG |
STABILISED SOLID COMPOSITIONS OF FACTOR VIIa POLYPEPTIDES
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
KR20050118669A
(ko)
*
|
2003-02-01 |
2005-12-19 |
뉴랄랩 리미티드 |
가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
|
|
EP1605968A2
(en)
*
|
2003-03-18 |
2005-12-21 |
Novo Nordisk Health Care AG |
Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
|
|
US7897734B2
(en)
*
|
2003-03-26 |
2011-03-01 |
Novo Nordisk Healthcare Ag |
Method for the production of proteins
|
|
CA2519408C
(en)
*
|
2003-04-04 |
2011-01-18 |
Genentech, Inc. |
High concentration antibody and protein formulations
|
|
ATE454900T1
(de)
|
2003-05-23 |
2010-01-15 |
Novo Nordisk Healthcare Ag |
Stabilisierung von proteinen in lösung
|
|
TWI374893B
(en)
*
|
2003-05-30 |
2012-10-21 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
JP4658041B2
(ja)
*
|
2003-06-25 |
2011-03-23 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
Ｖｉｉ因子ポリペプチドの液体組成物
|
|
EP1644030B1
(en)
*
|
2003-07-01 |
2009-10-28 |
Novo Nordisk Health Care AG |
Liquid, aqueous pharmaceutical composition of factor vii polypeptides
|
|
AU2004264282B2
(en)
*
|
2003-08-14 |
2010-10-14 |
Novo Nordisk Health Care Ag |
Liquid, aqueous pharmaceutical composition of Factor VII polypeptides
|
|
JP2007519623A
(ja)
|
2003-12-19 |
2007-07-19 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
Ｖｉｉ因子ポリペプチドの安定化された組成物
|
|
JP5037331B2
(ja)
|
2004-03-19 |
2012-09-26 |
バクスター・インターナショナル・インコーポレイテッド |
出血性障害の処置のための第ｉｘａ因子
|
|
ES2390082T5
(es)
*
|
2004-06-30 |
2018-01-19 |
Nektar Therapeutics |
Conjugados de resto de Factor IX y polímeros
|
|
US20060051347A1
(en)
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
|
US7625560B2
(en)
*
|
2004-12-15 |
2009-12-01 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
WO2006066171A1
(en)
*
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Amyloid βετα antibodies for use in improving cognition
|
|
US8916165B2
(en)
|
2004-12-15 |
2014-12-23 |
Janssen Alzheimer Immunotherapy |
Humanized Aβ antibodies for use in improving cognition
|
|
RU2007124933A
(ru)
*
|
2005-01-28 |
2009-03-10 |
Вайет (Us) |
Стабилизированные жидкие полипептидные составы
|
|
GT200600031A
(es)
*
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
|
DE602006018622D1
(de)
*
|
2005-06-30 |
2011-01-13 |
Ge Healthcare Bio Sciences |
Nachweisverfahren für die genexpression
|
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
SI2364691T1
(sl)
|
2006-06-16 |
2013-08-30 |
Regeneron Pharmaceuticals, Inc. |
Formulacije antagonista VEGF, primerne za intravitrealno dajanje
|
|
AU2007234612B2
(en)
*
|
2006-12-14 |
2013-06-27 |
Johnson & Johnson Regenerative Therapeutics, Llc |
Protein stabilization formulations
|
|
US8449520B2
(en)
*
|
2007-03-19 |
2013-05-28 |
HemCon Medical Technologies Inc. |
Apparatus and methods for making, storing, and administering freeze-dried materials such as freeze-dried plasma
|
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
CA2683317C
(en)
|
2007-04-26 |
2014-12-16 |
Bayer Healthcare Llc |
Stabilization of liquid solutions of recombinant protein for frozen storage
|
|
MX2009012964A
(es)
*
|
2007-06-01 |
2010-01-14 |
Acologix Inc |
Formulacion de peptido estable a alta temperatura.
|
|
US7678764B2
(en)
|
2007-06-29 |
2010-03-16 |
Johnson & Johnson Regenerative Therapeutics, Llc |
Protein formulations for use at elevated temperatures
|
|
US8613920B2
(en)
|
2007-07-27 |
2013-12-24 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
JP5323832B2
(ja)
|
2007-08-07 |
2013-10-23 |
アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー |
酸性水溶液中にｇｄｆ−５を含むタンパク質製剤
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
JP5599778B2
(ja)
*
|
2008-04-14 |
2014-10-01 |
デピュイ・シンセス・プロダクツ・エルエルシー |
液体緩衝ｇｄｆ−５製剤
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
EP2403874A1
(en)
|
2009-03-06 |
2012-01-11 |
Genentech, Inc. |
Antibody formulation
|
|
EP2538967A1
(en)
*
|
2010-02-24 |
2013-01-02 |
Arecor Limited |
Stable compositions of factor ix
|
|
SG10201502587SA
(en)
|
2010-03-01 |
2015-06-29 |
Bayer Healthcare Llc |
Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
|
|
US8613919B1
(en)
|
2012-08-31 |
2013-12-24 |
Bayer Healthcare, Llc |
High concentration antibody and protein formulations
|
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
|
JP6389868B2
(ja)
*
|
2013-03-15 |
2018-09-12 |
ジーピービー デット ホールディングス トゥー エルエルシー |
サンプルの発光及び蛍光測定を行うための装置及び関連する方法
|
|
JP6387392B2
(ja)
*
|
2013-03-15 |
2018-09-05 |
バイオベラティブ セラピューティクス インコーポレイテッド |
第ｉｘ因子ポリペプチド製剤
|
|
WO2015148444A1
(en)
|
2014-03-24 |
2015-10-01 |
Biogen Ma Inc. |
Lyophilized factor ix formulations
|
|
EP3384049B1
(en)
|
2015-12-03 |
2023-08-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
|
|
EP3694322B1
(en)
|
2017-10-09 |
2024-07-03 |
Terumo BCT Biotechnologies, LLC |
Lyophilization container and method of using same
|
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
|
JP7541993B2
(ja)
|
2019-03-14 |
2024-08-29 |
テルモ ビーシーティー バイオテクノロジーズ，エルエルシー |
凍結乾燥用ローディングトレイ組立体、凍結乾燥システム及び凍結乾燥方法
|